In the News
-
Xconomy: Acceleron, Celgene Take Aim at Amgen’s Multi-Billion Dollar Anemia Market
+ VIEW FULL In the News -
BioWorld Today: New Acceleron, Celgene Deal Anything But ‘Anemic’
+ VIEW FULL In the News -
Scrip Intelligence: Celgene Pays Acceleron $25M Upfront Under Anemia Drug Partnership
+ VIEW FULL In the News -
FierceBiotech Names Acceleron Pharma as One of the “Fierce 15” of 2010
+ VIEW FULL In the News -
Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States
+ VIEW FULL In the News -
Pink Sheet Daily: Acceleron’s GDF Therapies: Just Different Enough?
+ VIEW FULL In the News -
BioCentury: Bone Loss is Acceleron’s Gain
+ VIEW FULL In the News -
BioWorld Today: Acceleron, Celgene in Potential $1.8B Bone Loss Collaboration
+ VIEW FULL In the News -
BioWorld Today: Acceleron Series C Gets $31M for Bone, Muscle Growth Bids
+ VIEW FULL In the News -
Technology Review: Mimicking the Massively Muscular
+ VIEW FULL In the News -
Pharmaceutical Executive: Acceleron Pharma’s Pipeline Selected to Top 7 Most Exciting Future Therapies and Technologies
+ VIEW FULL In the News -
Boston Globe: Super-buff cattle may hold key to treating muscular diseases
+ VIEW FULL In the News -
Start-Up: Acceleron Pharma, Inc.-Releasing the Brakes on Bone and Muscle Growth
+ VIEW FULL In the News -
GEN: Acceleron Takes on Bone & Muscle Repair
+ VIEW FULL In the News -
Forbes: Superbaby Serum
+ VIEW FULL In the News -
Red Herring: Growing a Backbone; VC’s Finance Bone Loss Treatment
+ VIEW FULL In the News -
BioWorld Today: Acceleron Secures $30M in Series B
+ VIEW FULL In the News -
BioCentury: Acceleron: Value in the Wallflower
+ VIEW FULL In the News